Lactobacillus plantarum 299v reduces colonisation of Clostridium difficile in critically ill patients treated with antibiotics

Acta Anaesthesiologica Scandinavica

Volumn 52, Issue 8, 2008, Pages 1096-1102

  Klarin, B ^a   Wullt, M ^a   Palmquist, I ^a   Molin, G ^b   Larsson, A ^c   Jeppsson, B ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM; CEPHALOSPORIN; CORTICOSTEROID; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; SUGAR;

ADULT; AGED; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE; CRITICALLY ILL PATIENT; ENTERIC FEEDING; FECES ANALYSIS; FEMALE; FERMENTED PRODUCT; HOSPITALIZATION; HUMAN; INFECTION; INFLAMMATION; INTENSIVE CARE UNIT; INTESTINE MUCOSA PERMEABILITY; LACTOBACILLUS PLANTARUM; MALE; OAT; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLOSTRIDIUM DIFFICILE; CRITICAL ILLNESS; FECES; FEMALE; HUMANS; LACTOBACILLUS PLANTARUM; MALE; MIDDLE AGED;

EID: 49849086927     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2008.01748.x     Document Type: Article

References (38)

1. Pépin J, Valiquette L, Alary M-E, Villemure P, Pelletier A, Forget K, Pépin K, Chouinard D. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Can Med Asso J 2004 171 (5) : 466 72.
2. Nelson DE, Auerbach SB, Baltch AL, Desjardin E, Beck-Sague C, Rheal C, Smith RP, Jarvis WR. Epidemic Clostridium difficile diarrhea: role of second- and third-generation cephalosporins. Infect Control Hosp Epidemiol 1994 15 : 88 94.
3. Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L. Emergence of fluoroquinolonesas the predominant risk factor for Clostridium difficile associated diarrhe: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005 41 : 1254 60.
4. Anand A, Bashey B, Mir T, Glatt AE. Epidemiology, clinical manifestations, and outcome of Clostridium difficile - associated diarrhea. Am J Gastroenterol 1994 89 : 519 23.
5. Karlström O, Fryklund B, Tullus K, Burman LG. A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. Clin Infect Dis 1998 26 : 141 5.
6. Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 2007 142 (7) : 624 31.
7. McFarlnad LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 1990 162 : 678 84.
8. McFarland LV. Diarrhea acquired in the hospital. Gastroenterol Clin North Am 1993 22 : 563 77.
9. Wiström J, Norrby SR, Myhre EB, Eriksson S, Granström G, Lagergren L, Rnglund G, Nord CE, Svennungson B. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001 47 : 43 50.
10. McDonald LC, Killgore GE, Thompson A, Owens Jr. RC, Kazakova SV, Sambol SP, Johnson S, Gerding DN. An epidemic, toxin gene-variant strain of Clostridium difficile. N Eng J Med 2005 353 : 2433 41.
11. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, René P, Monczak Y, Dascal A. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Eng J Med 2005 353 : 2442 9.
12. Kuijper EJ, Coignard B, Tüll P. on behalf of the ESCMID Study Group for Clostridium difficile (ESGCD), EU Member States. The European Centre for Disease Prevention and Control (ECDC). Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006 Oct 12 (Suppl. 6) : 2 18.
13. Chatila W, Manthous CA. Clostridium difficile causing sepsis and an acute abdomen in critically ill patients. Crit Care Med 1995 23 : 1146 50.
14. Lowenkron SE, Waxner J, Khullar P, Ilowite JS, Niederman MS, Fein AM. Clostridium difficile infection as a cause of severe sepsis. Int Care Med 1996 22 : 990 4.
15. Dobson G, Hickey C, Trinder J. Clostridium difficile colitis causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome. Int Care Med 2003 29 : 1030.
16. Kenneally C, Rosini JM, Skrupky LP, Doherty JA, Hollands JM, Martinez E, McKenzie W, Murphy T, Smith JR, Micek ST, Kollef MH. Analysis of 30-day mortality for Clostridium difficile-associated disease in the ICU setting. Chest 2007 132 : 418 24.
17. Marra AR, Edmond MB, Wenzel RP, Bearman GML. Hospital-acquired Clostridium difficile-associated disease in the intensive care unit setting: epidemiology, clinical course and outcome. BMC Infect Dis 2007 7 : 42.
18. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer G, Moyer KA, Melcher SA, Bowen KE, Cox JL, Noorani Z et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficiledisease. JAMA 1994 271 : 1913 8.
19. Wullt M, Hagslätt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 2003 35 : 365 7.
20. Johansson M-L, Molin G, Jeppsson B, Nobaek S, Ahrné S, Bengmark S. Administration of different Lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora. Appl Environ Microbiol 1993 59 : 15 20.
21. Klarin B, Johansson M-L, Molin G, Larsson A, Jeppsson B. Adhesion of the probiotic bacterium Lactobacillus plantarum 299v onto the gut mucosa in critically ill patients: a randomised open trial. Crit Care 2005 9 : R285 93.
22. McNaught CE, Woodcock NP, Anderson ADG, MacFie J. A prospective randomised trial of probiotics in critically ill patients. Clin Nutr 2005 24 : 211 9.
23. Rayes N, Seehofer D, Hansen S, Boucsein K, Muller AR, Serke S, Bengmark S, Neuhaus P. Early enteral supply of Lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 2002 74 : 123 8.
24. Oláh A, Belágyi T, Issekutz Á, Gamal ME, Bengmark S. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis, 2002 89 : 1103 7.
25. Adawi D, Molin G, Ahrné S, Jeppsson B. Safety of the probiotic strain Lactobacillus plantarum DSM 9843 (=strain 299v) in an endocarditis animal model. Microbial Ecol Health Dis 2002 14 : 50 3.
26. Johansson M-L, Quednau M, Molin G, Ahrné S. Randomly Amplified Polymorphic DNA (RAPD) for rapid typing of Lactobacillus plantarum strains. Lett Appl Microbiol 1995 21 : 155 9.
27. Sørensen SH, Proud FJ, Adam A, Rutgers HC, Batt RM. A novel HPLC method for the simultaneous quantification of monosaccharides and disaccharides used in tests of intestinal function and permeability. Clin Chim Acta 1993 221 : 115 25.
28. Hickson M, D'Souza AL, Muthu N, Rogers TR, Want S, Rajkumar C, Bulpitt CJ. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007 335 (7610) : 80.
29. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006 101 : 812 22.
30. Buggy BP, Wilson KH, Fekety R. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003 54 : 243.
31. Jump RLP, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother 2007 51 : 2883 7.
32. Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther 2006 24 : 613 9.
33. Timmerman HM, Niers LE, Ridwan BU, Koning CJM, Mulder L, Akkermans LMA, Rombouts FM, Rijkers GT. Design of a multispecies probiotic mixture to prevent infectious complications in critically ill patients. Clin Nutr 2007 26 : 450 9.
34. Ridwan BU, Koning CJ, Besselink MG, Timmerman HM, Brouwer EC, Verhoef J, Gooszen HG, Akkermans LMA. Antimicrobial activity of a multispecies probiotic (Ecologic 641) against pathogens isolated from infected pancreatic necrosis. Lett Appl Microbiol 2008 46 : 61 7.
35. Besselink MG, vanSantvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Rosman C, Ploeg RJ, Brink MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, van der Harst E, van Eijck CH, Cuesta MA, Akkermans LM, Gooszen HG. for the Dutch Acute Pancreatitis Study Group. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008 371 : 651 9.
36. Oudemans-van Straaten HM, J, van der Voort PH, Hoek FJ, Bosman RJ, van der Spoel JI, Zandstra DF. Pitfalls in gastrointestinal permeability measurement in ICU patients with multiple organ failure using differential sugar absorption. Int Care Med 2002 28 : 130 8.
37. Fink MP. Clinical tests of gastrointestinal permeability that rely on the urinary recovery of enterally administered probes can yield invalid results in critically ill patients. Int Care Med 2002 28 : 103 4.
38. Travis S, Menzies I. Intestinal permeability: functional assessment and significance. Clinical Science 1992 82 : 471 88.